People: Endologix Inc (ELGX.O)

Summary

Name	Age	Since	Current Position
John McDermott		2012	Chairman of the Board, President, Chief Executive Officer
Shelley Thunen	60	2013	Chief Financial Officer
Robert Mitchell	50	2010	President, Global Strategic Initiatives
Leo Greenstein	36	2011	Vice President - Finance, Corporate Controller
Todd Abraham	48	2010	Vice President - Operations
Joseph DeJohn	51	2008	Vice President - Sales
Ruth Lyons	56	2011	Vice President - Global Marketing
Charles Love		2012	Vice President - Clinical Affairs
Stefan Schreck	52	2004	Vice President - Technology
Gary Sorsher	47	2008	Vice President - Quality
Martin Tyler	43	2004	Director - Marketing
Janet Fauls	49	2012	Director - Regulatory Affairs
Roderick de Greef	51	2003	Independent Director
Daniel Lemaitre		2009	Independent Director
Guido Neels	63	2010	Independent Director
Gregory Waller	63	2003	Independent Director
Thomas Wilder	48	2010	Independent Director
Nick Laudico		2012	IR Contact

» Insider Trading

Biographies

Name	Description
John McDermott	Mr. John McDermott is Chairman of the Board, President, Chief Executive Officer of the Endologix,Inc. He joined the company in May 2008 as President and Chief Executive Officer. Mr. McDermott has over 20 years of executive management, sales, marketing, and finance experience in the vascular device industry. From 2002 to 2007 he served as President of Bard Peripheral Vascular, a division of C.R. Bard, Inc. Mr. McDermott previously served as President of Global Sales for C.R. Bard’s vascular surgery and endovascular businesses with responsibilities for managing a worldwide direct sales force with more than 200 representatives. Prior to that, he served for four years as President of C.R. Bard’s division IMPRA, Inc., where he was responsible for global operations, including sales, marketing, research and development, manufacturing, and finance. From 1990 to 1996, Mr. McDermott served as Chief Financial Officer and later Vice President and Chief Operating Officer of IMPRA, Inc., prior to its acquisition by C.R. Bard. He is an active leader within the vascular community and is currently on the board of directors of the International Society of Endovascular Specialists.
Shelley Thunen	Ms. Shelley B. Thunen has been appointed as Chief Financial Officer of Endologix, Inc. effective January 02, 2013. Ms. Thunen's experience in the medical technology industry includes having served as Chief Financial Officer of two Nasdaq-listed companies and several private companies in the sector. Prior to joining Endologix, Ms. Thunen served as Associate General Manager of Alcon LenSx, Inc. (acquired August 2010), a wholly owned Alcon company that develops and manufactures a laser and related disposable for use in cataract surgery. Prior to the acquisition by Alcon, Ms. Thunen served as Chief Financial Officer and Vice President, Operations at that company since 2009. She also served on the LenSx Board of Directors and as chairperson of the Audit Committee from 2008 until its acquisition in 2010. Ms. Thunen was a Board Member and chairperson of the Audit Committee for eyeonics, inc., a developer and manufacturer of accommodating intraocular lenses for the treatment of cataracts, from 2007 to 2008 until eyeonics was acquired by Bausch & Lomb, a diversified ophthalmology company. From 2007 to 2009, Ms. Thunen was Chief Financial Officer of TherOx, Inc., a privately-held medical device company focused on cardiovascular therapeutics. From 2004 to 2007, Ms. Thunen was Executive Vice President and Chief Financial Officer, and from 2001 to 2004 Chief Financial Officer of IntraLase Corp., a Nasdaq-listed ophthalmology company that designs, develops and manufactures the IntraLase laser and disposable product, used in LASIK surgery. IntraLase was acquired by Advanced Medical Optics, Inc., an NYSE-listed company, in 2007. Ms. Thunen received a B.A. in Economics, cum laude, and a Masters of Business Administration (MBA), both from the University of California at Irvine.
Robert Mitchell	Mr. Robert D. Mitchell is President, Global Strategic Initiatives of Endologix Inc. since December 2010 as President, International. Prior to joining the company, Mr. Mitchell served as President and Chief Executive Officer of Nellix, Inc. from February 2008 until acquisition of Nellix in December 2010. From November 2006 to February 2008, Mr. Mitchell served as Executive Vice President and Chief Operating Officer of AngioDynamics, Inc., a publicly-traded medical device company. From 2005 to 2006, Mr. Mitchell served as Chairman, President and Chief Executive Officer of Millimed Holdings, Inc., a privately-held medical device company based in Roskilde, Denmark. From 2004 to 2005, Mr. Mitchell served as Vice President of Worldwide Sales for Align Technology, Inc., a publicly-traded company. From 1987 to 2004, Mr. Mitchell held various positions with Cook Incorporated, a privately-held medical device company, including Vice President and Director, Global Sales and Marketing for various business units including diagnostic and interventional, endovascular, critical care. Mr. Mitchell holds a B.S. from the University of Utah and an M.B.A. from Indiana Wesleyan University.
Leo Greenstein	Mr. Leo M. Greenstein is Vice President - Finance, Corporate Controller of Endologix Inc. since May 2011. He has more than 13 years of finance and accounting experience. Prior to joining the company, he served as Senior Director of Finance and SEC Reporting of Clarient, Inc., a molecular diagnostics company for cancer therapeutics. In that role, he was responsible for all aspects of Clarient’s SEC and NASDAQ compliance, technical accounting, tax compliance, select legal and business operations, and oversight of risk management. He also assisted in the raising of capital through both debt and equity, and completing certain acquisitions and divestitures. Before joining Clarient, he was the Assistant Controller of its majority shareholder, Safeguard Scientifics, Inc., a publicly-registered venture capital firm located in the Philadelphia area that provides growth capital and management support to life science and technology companies. Mr. Greenstein received his B.A. in Accounting from Arcadia University in Glenside, Pennsylvania in 1999, where he also served as an Adjunct Professor of Accounting in 2008 and 2009. He began his career in Philadelphia, spending eight years in public accounting, reaching the level of Audit Manager with PricewaterhouseCoopers LLP. While working in public accounting, he received a law degree from Temple University’s Beasley School of Law. Mr. Greenstein is a Certified Public Accountant, with an active license in California, and has completed the California Bar Examination.
Todd Abraham	Mr. Todd G. Abraham is Vice President - Operations of Endologix, Inc. since July 2010. Prior to joining the company, Mr. Abraham held several management positions at Edwards Lifesciences Corporation, a publicly-traded medical device company, including Vice President, Glucose Monitoring, Vice President, Global Supply Chain & Logistics, and Vice President, Manufacturing. Prior to joining Edwards Lifesciences, Mr. Abraham served as Vice President and General Manager of Sterilis, Inc., a privately-held medical device company. Prior to that, Mr. Abraham spent 14 years at Cordis, a Johnson & Johnson Company, holding several positions of increasing responsibility in operations and product development. Mr. Abraham holds a B.A. in Economics from Duke University and completed graduate work in Engineering Management at the University of South Florida.
Joseph DeJohn	Mr. Joseph A. DeJohn is Vice President - Sales of Endologix Inc. since July 2008. He has more than 20 years of sales management experience in the medical device industry, including serving 17 years at C.R. Bard. During his tenure at C.R. Bard, he held sales management positions with increasing responsibilities, serving the last six years as Vice President of Sales of the Peripheral Vascular Division. In this position, he was responsible for managing a 200-person sales organization and played a leadership role in strategic planning, budgeting, recruitment, professional development, national accounts, and customer service. Prior to that, Mr. DeJohn was Director of Sales of C.R. Bard’s Peripheral Technologies Division. Before joining C.R. Bard, Mr. DeJohn served five years with Bausch & Lomb Corporation in various sales management positions. Mr. DeJohn holds a B.S. in Education from Bowling Green State University
Ruth Lyons	Ms. Ruth Lyons is Vice President - Global Marketing of Endologix, Inc., since August 2011. Previously, Ms. Lyons spent ten years in leadership positions in marketing, portfolio planning and business development at St. Jude Medical’s Cardiac Rhythnin Management Division. Most recently Ms. Lyons held the position of VP Marketing, Emerging Technologies where she had primary responsibilities for all product planning and marketing of new technologies and future growth drivers. Prior to St. Jude Medical, Ms. Lyons held senior marketing positions at Johnson & Johnson’s Cordis Cardiology, Biosense Webster and DePuy Orthopaedics divisions as well as ten years in sales and marketing at Baxter Healthcare. Ms. Lyons has an M.B.A. from the University of Southern California.
Charles Love	Mr. Charles Love has been appointed as Vice President - Clinical Affairs of Endologix, Inc., effective 01 October 2012. Prior to joining Endologix, Mr. Love served as Vice President of Clinical and Regulatory Compliance at CircuLite, Inc., a privately held medical device company developing disruptive solutions for the treatment of chronic heart failure. He has also served as a consultant and held management level Clinical Affairs, Regulatory and Strategic Development positions for a variety of medical device companies, including Medtronic, CoreValve, nContact Surgical, Inc., Ventracor Limited, and Converge Medical, Inc. His experience also includes senior management positions at Ramus Medical Technologies and Autogenics. He serves on the Board of Directors for Loma Vista Medical and is on the Technical Advisory Board for Dexteritie Surgical. Mr. Love received a B.A. in Biology from Westmont College. He also completed undergraduate work in Engineering at Gonzaga University and completed management programs at the University of California and Stanford University.
Stefan Schreck	Dr.. Stefan G. Schreck , Ph.D., is Vice President - Technology of Endologix, Inc. since February 2004. Dr. Schreck has more than 20 years of experience in research and development of medical products. Prior to joining the company, Dr. Schreck held increasingly more responsible research and development management positions in the medical device industry. From May 1995 to April 2000, Dr. Schreck served as Director of Research in Baxter Healthcare’s Heart Valve Division. From April 2000 to August 2002, Dr. Schreck served as Senior Director, Research and Development at Edwards Lifesciences and was responsible for the development of all surgical heart valve repair and replacement products. From August 2002 to February 2004, Dr. Schreck served as President and Chief Executive Officer of MediMorph Solutions Inc., an engineering and management consulting firm for the medical device industry, which he founded.
Gary Sorsher	Mr. Gary I. Sorsher is Vice President - Quality of Endologix, Inc., since October 2008. He brings 20 years of quality assurance experience. Prior to that, he served for two years as Director of Quality Engineering at Bard Peripheral Vascular, where he oversaw quality assurance operations for Bard Peripheral Vascular and Bard Biopsy Systems. Prior to that, he spent 14 years at Cordis, a Johnson & Johnson Company, holding several positions with increasing responsibility during his tenure. Among these, he served as Director of Quality Assurance, New Product Development and as the senior quality assurance representative for Cordis’ Global Commercialization Team responsible for drug eluting stents, stent delivery systems, and angioplasty products. Mr. Sorsher holds a B.S. and an M.S. in Electrical Engineering from Byelorussian Polytechnic Institute, Minsk, Belarus.
Martin Tyler	Mr. Martin Tyler is Director - Marketing of Endologix Inc. Assuming increasing responsibilities through the present time including management of International Sales efforts for the past 3 years, he is currently Vice President, Global Marketing. He brings more than 19 years of marketing and sales management experience in the medical device industry. He spent 12 years as head of marketing for start up companies Accumetrics, Sub-Q, and Vertis Neuroscience, launching new products into the cardiovascular, vascular, and neuro markets, respectively. Mr. Tyler started his career with 6 years at Baxter Healthcare in various sales and marketing positions, and then worked as a Senior Product Manager for the former USCI division (Interventional Cardiology) of C.R. Bard. Mr. Tyler holds a B.S. in Marketing from the University of Tennessee.
Janet Fauls	Ms. Janet Fauls is Director - Regulatory Affairs of Endologix Inc. Assuming increasing responsibilities through the present time, she is currently Vice President, Regulatory and Clinical Affairs. Ms. Fauls has more than 20 years of experience in the medical device and biopharmaceutical industries. From 1987 to 1997, Ms. Fauls held increasingly responsible positions in Quality and Regulatory Affairs for Allergan, Inc. and Alliance Pharmaceuticals. From 1997 to 2001, Ms. Fauls served in a Regulatory Affairs management capacity at Edwards Lifesciences with primary responsibility for surgical heart valve repair and replacement products and related disposable products. From 2001 to November 2005, Ms. Fauls served as Vice President, Regulatory, Quality and Clinical Affairs for Cardiogenesis Corporation, a medical device company specializing in laser-based cardiovascular therapies. Ms. Fauls holds a B.S. in Chemistry from the University of California, Santa Barbara.
Roderick de Greef	Mr. Roderick De Greef, is no longer Independent Director of Endologix, Inc., effective May 23, 2013. Mr. de Greef is the principal of Taveyanne Capital Advisors, Inc., a corporate firm providing finance consulting services. Since November 2008, Mr. de Greef has been Chairman of the board of directors of Cambridge Heart, Inc., a publicly-traded company that develops and commercializes non-invasive diagnostic tests for cardiac disease, where he was previously the Chief Financial Officer from October 2005 to July 2007. Prior to that, Mr. de Greef served as the Executive Vice President, Chief Financial Officer and Secretary of Cardiac Science, Inc. from March 2001 to September 2005. From 1995 to 2001, Mr. de Greef provided corporate finance advisory services to a number of early stage companies including Cardiac Science, Inc., where he was instrumental in securing equity capital beginning in 1997, and advising on merger and acquisition activity. Mr. de Greef has a B.A. in Economics and International Relations from California State University, San Francisco and an M.B.A. from the University of Oregon. Mr. de Greef also serves on the boards of directors of BioLife Solutions, Inc. a publicly held life science company, and Genesis Biosciences, a privately held company.
Daniel Lemaitre	Mr. Daniel Lemaitre is Independent Director of Endologix, Inc. since December 11, 2009. Mr. Lemaitre most recently served as the President and Chief Executive Officer of CoreValve, a privately-held company focused on percutaneous aortic valve replacement, from April 2008 until its acquisition by Medtronic, Inc., a publicly-traded medical device company, in April 2009. From 2005 until March 2008, Mr. Lemaitre was a Senior Vice President at Medtronic, where he led the company’s strategic planning and corporate development. Prior to joining Medtronic, Mr. Lemaitre spent 28 years in the medical device field as an investment analyst. This included 18 years with SG Cowen, where he was a managing director and led the healthcare research team, and six years with Merrill Lynch. Mr. Lemaitre holds a B.A. in Economics from Bethany College and an M.B.A. from Bowling Green State University. Mr. Lemaitre also serves on the board of directors of Globus Medical, Inc., a privately-held manufacturer of spinal implants.
Guido Neels	Mr. Guido J. Neels is Independent Director of Endologix Inc., since December 10, 2010. Mr. Neels has been a Managing Director at Essex Woodlands Health Ventures, Inc., or Essex Woodlands, a venture capital firm, since 2006. Prior to joining Essex Woodlands, Mr. Neels served in a variety of management positions at Guidant Corporation, a developer of cardiovascular medical products. From July 2004 until retiring in November 2005, Mr. Neels served as Guidant’s Chief Operating Officer, where he was responsible for the global operations of Guidant’s four operating units: Cardiac Rhythm Management, Vascular Intervention, Cardiac Surgery, and Endovascular Solutions. From December 2002 to July 2004, Mr. Neels served as Guidant’s Group Chairman, Office of the President, responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations. In January 2000, Mr. Neels was named Guidant’s President, Europe, Middle East, Africa and Canada. In addition, Mr. Neels served as Guidant’s Vice President, Global Marketing, Vascular Intervention, from 1996 to 2000 and as Guidant’s General Manager, Germany and Central Europe, from 1994 to 1996. Mr. Neels has a business engineering degree from the University of Leuven in Belgium and an M.B.A. from the Stanford University Graduate School of Business. Mr. Neels served on the boards of directors of Biopure Corporation, a publicly-traded medical device company, from 2005 to 2009, Lemaitre Vascular, Inc., a publicly-traded medical device company, from 2006 to 2008, and Nellix, Inc., a privately-held medical device company, from 2006 until its acquisition by the company in December 2010. Mr. Neels currently serves on the boards of directors of 480 Medical, Inc., ROX Medical, Inc., Entellus Medical, Inc., Oraya Therapeutics, Inc., Arsenal Medical, Inc., EndGenitor Technologies, Inc., and White Pine Medical, Inc., all privately-held medical device companies.
Gregory Waller	Mr. Gregory D. Waller, is Independent Director of Endologix, Inc since November 2003. Mr. Waller also serves on the board of Sunshine Heart Corporation, a publicly traded company, as Audit Committee Chairman and is currently the Chief Financial Officer of Ulthera Corporation, a privately held company that sells an ultrasound device used for non-invasive brow lifts. From March 2006 until April 2011, Mr. Waller was Chief Financial Officer of Universal Building Products, a manufacturer of concrete construction accessories. Previous to that, Mr. Waller has been in retirement except for board directorships. Mr. Waller served as Vice President-Finance, Chief Financial Officer and Treasurer of Sybron Dental Specialties, Inc., a manufacturer and marketer of consumable dental products, from August 1993 until his retirement in May 2005 and was formerly the Vice President and Treasurer of Kerr, Ormco Corporation, and Metrex. Mr. Waller joined Ormco Corporation in December 1980 as Vice President and Controller and served as Vice President of Kerr European Operations from July 1989 to August 1993. Mr. Waller has an M.B.A. with a concentration in Accounting from California State University, Fullerton. Mr. Waller also served on the board of directors and audit committee of Cardiogenesis Corporation, a publicly-traded company until its acquisition by Cryolife in 2011. Mr. Waller also served on the boards of directors of Alsius Corporation, a publicly-traded company, from June 2007 to September 2009 until its acquisition by Zoll, Biolase Technology, Inc., a publicly-traded company, from October 2009 to August 2010, Clarient, Inc., a publicly-traded company which was acquired by General Electric Company on December 22, 2010, and SenoRx, Inc., a publicly-traded company which was acquired by C.R. Bard, Inc. on July 6, 2010.
Thomas Wilder	Mr. Thomas C. Wilder, III is Independent Director of Endologix Inc. since May 2010. He currently serves as the President and Chief Executive Officer of Sequent Medical, Inc., a privately-held medical device company focused on developing innovative devices for the treatment of neurovascular disease, since February 2010. Concurrently, he also serves on the board of Benvenue Medical, a privately-held medical device company focused on the design, manufacture, and marketing of cutting edge products for the rapidly growing minimally invasive spinal surgery market. From May 2009 to February 2010, Mr. Wilder consulted with several medical device companies. From April 2006 to April 2009, Mr. Wilder served as the President and Chief Executive Officer of Photothera, Inc. From 2002 through January 2006, Mr. Wilder served at Micro Therapeutics, Inc. as President and Chief Executive Officer. Following the merger of Micro Therapeutics, Inc. into ev3 Inc. in January 2006, Mr. Wilder served as President, ev3 Neurovascular until April 2006. From 1991 to 2002, Mr. Wilder served in various roles for Medtronic, Inc. Mr. Wilder has a B.A. in Economics from Stanford University and an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management.
Nick Laudico

Basic Compensation

Name	Fiscal Year Total
John McDermott	951,970
Shelley Thunen	--
Robert Mitchell	499,775
Leo Greenstein	--
Todd Abraham	495,223
Joseph DeJohn	482,319
Ruth Lyons	--
Charles Love	--
Stefan Schreck	488,793
Gary Sorsher	--
Martin Tyler	--
Janet Fauls	262,852
Roderick de Greef	--
Daniel Lemaitre	--
Guido Neels	--
Gregory Waller	--
Thomas Wilder	--
Nick Laudico	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
John McDermott	72,935	402,601
Shelley Thunen	0	0
Robert Mitchell	0	0
Leo Greenstein	0	0
Todd Abraham	0	0
Joseph DeJohn	0	0
Ruth Lyons	0	0
Charles Love	0	0
Stefan Schreck	121,400	104,176
Gary Sorsher	0	0
Martin Tyler	0	0
Janet Fauls	0	0
Roderick de Greef	0	0
Daniel Lemaitre	0	0
Guido Neels	0	0
Gregory Waller	0	0
Thomas Wilder	0	0
Nick Laudico	0	0

Insider Trading

Name	Shares Traded	Price
TYLER MARTIN	15,000	$15.42
TYLER MARTIN	28,606	$5.33
TYLER MARTIN	13,606	$15.45
TYLER MARTIN	1,394	$5.33
TYLER MARTIN	1,394	$15.50
SORSHER GARY I	4,414	$16.02
SORSHER GARY I	676	$15.98
DE GREEF RODERICK	2,000	$15.81
DE GREEF RODERICK	2,500	$15.78
DE GREEF RODERICK	2,000	$15.77
SORSHER GARY I	1,100	$16.02
DE GREEF RODERICK	1,000	$15.84
DE GREEF RODERICK	12,000	$6.35
DE GREEF RODERICK	500	$15.83
SORSHER GARY I	1,723	$15.98
DE GREEF RODERICK	4,000	$15.80
DE GREEF RODERICK	1,000	$15.43
DE GREEF RODERICK	1,000	$15.45
DE GREEF RODERICK	3,500	$15.52
DE GREEF RODERICK	20,000	$8.26
DE GREEF RODERICK	8,500	$15.50
DE GREEF RODERICK	1,000	$15.46
DE GREEF RODERICK	8,000	$6.35
DE GREEF RODERICK	2,000	$15.51
DE GREEF RODERICK	1,000	$15.40

» Full list on Insider Trading

People: Endologix Inc (ELGX.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: